Michele Luche

Michele is an established business and science executive with more than 30 years of research experience, including over 20 years in biotech/pharma, leading small molecule drug discovery efforts from target identification through clinical trials and marketed drug products for oncology and CNS disorders, including SUTENT®, Pfizer’s marketed kinase inhibitor for renal cell carcinoma.  In addition, Michele has held senior management positions within US and Asia CROs/CDMOs including Vice President of Global Drug Discovery for Curia, until her most recent appointment as Vice President for IRBM, formerly Merck’s Research Site and Center of Excellence in Rome, Italy which is now an independent, fully integrated discovery and early development contract organization focused on peptide, antibody and small molecule therapeutics, with the notable track record of oncology therapeutics, Zolinza ® and Zejula ®, and 2 anti-virals, Isentress® and Grazoprevir.